216
Views
29
CrossRef citations to date
0
Altmetric
Original Article

Treatment of pan-drug resistant Acinetobacter baumannii

, , &
Pages 195-199 | Received 21 Sep 2004, Accepted 05 Nov 2004, Published online: 08 Jul 2009

References

  • Wisplinghoff H, Perbix W, Seifert H. Risk factors for nosocomial bloodstream infections due to Acinetobacter baumannii: a case control study of adult burn patients. Clin Infect Dis 1999;28:59–66.
  • Corbella X, Montero A, Pujol M, Dominguez MA, Ayats J, Argerich MJ, et al. Emergence and rapid spread of carbape- nem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 2000;38:4086–95.
  • Aubert G, Guichard D, Vedel G. In vitro activity of cephalosporins alone and combined with sulbactam against various strains of Acinetobacter baumannii with different antibiotic resistance profiles. J Antimicrob Chemother 1996; 37:155–60.
  • Garcia-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jimenez-Jimenez FJ, Monterrubio-Villar J, Gili-Miner M. Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients. Crit Care Med 1999;27:1794–8.
  • Hsueh PR, Teng LJ, Chen CY, Chen WH, Yu CJ, Ho SW, Luh KT. Pan-drug resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis 2002;8:827–32.
  • Mahgoub S, Ahmed J, Glatt AE. Completely resistant Acinetobacter baumannii strains. Infect Control Hosp Epidemiol 2002;23:477–9.
  • Simor AE, Lee M, Vearncombe M, Jones-Paul L, Barry C, Gomez M, et al. An outbreak due to multiresistant Acinetobacter baumannii in a burn unit: risk factors for acquisition and management. Infect Control Hosp Epidemiol 2002;23: 261–7.
  • Levin AS, Gobara S, Mendes CMF, Cursino R, Sinto S. Enviromental contamination by multidrug- resistant Acinetobacter baumannii in an intensive care unit. Infect Control Hosp Epidemiol 2001;22:717–20.
  • Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 2000;31:101–6.
  • Koeleman JGM, Parlevliet GA, Dijkshoorn L, Savelkoul PHM, Vandenbroucke-Grauls CMJE. Nosocomial outbreak of multi-resistant Acinetobacter baumannii on a surgical ward: epidemiology and risk factors for acquisition. J Hosp Infect 1997;37:113–23.
  • Go ES, Urban C, Burns J, Kriswirth B, Eisner W, Mariano N, Mosinka-Snipas K. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994;344:1329–32.
  • Joly-Guillou ML, Decre D, Herrman JL, Bourdelier E, Bergogne- Berezin E. Bactericidal in vitro activity of lactams and ß lactamase inhibitors, alone or associated, against clinical strains of Acinetobacter baumannii: effect of combination with aminoglycosides. J Antimicrob Chemother 1995;36:619–29.
  • Mulin B, Talon D, Viel JF, Vincent C, Leprat R, Thouverez M, Michel-Briand Y. Risk factors for nosocomial colonization with multiresistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 1995;14:569–76.
  • Seifert H, Strate A, Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii; clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore) 1995; 74:340–9.
  • Chow AW, Wong J, Bartlett KH. Synergistic interactions of ciprofloxacin and extended spectrum β lactams or aminoglycosides against Acinetobacter calcoaceticus ss. Anitratus. Diagn Microbiol Infect Dis 1998;9:213–7.
  • Bataibar J, Correa H, Mariscal D, Gallego M, Valles J, Rello J. Risk factors for infection by Acinetobacter baumannii in intubated patients with nosocomial pneumonia. Chest 1997; 112:1050–4.
  • Corbella X, Ariza J, Arganuy C, Vuelta M, Tubau F, Sora M, et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother 1998; 42:793–802.
  • Wood GC, Hanes SD, Croce MA, Fabian TC, Bradley AB. Comparison of ampicillin-sulbactam and imipenemcilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002;34:1425–30.
  • Urban C, Go E, Mariano N, Berger BJ, Avraham I, Rubin D, Rahal JJ. Effect of sulbactam on infections caused by imipenem resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993;167:448–51.
  • Appleman MD, Belzberg H, Citron DM, Heseltine PNR, Yellin AE, Murray J, Berne TV. In vitro activities of non- traditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak. Antimicrob Agents Chemother 2000;44:1035–40.
  • Kuah BG, Kumarasinghe G, Doran J, Chang HR. Antimicrobial susceptibilities of clinical isolates of Acinetobacter baumannii from Singapore. Antimicrob Agents Chemother 1994;38:2502–3.
  • Theaker C, Azadian B, Soni N. The impact of Acinetobacter baumannii in the intensive care unit. Anaesthesia 2003;58: 271–4.
  • Das I, Lambert P, Hill D, Noy M, Bion J, Elliott T. Carbapenem resistant Acinetobacter and role of curtains in an outbreak in intensive care units. J Hosp Infect 2002;50: 110–4.
  • Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP, Seifert H. Nosocomial bloodstream infections caused by Acinetobacter species in United States Hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis 2000;31:690–7.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.